When the first antiepileptic drug fails in a patient with juvenile myoclonic epilepsy

Practical Neurology

Volumn 10, Issue 4, 2010, Pages 208-218

  Nicolson, Andrew ^a   Marson, Anthony G ^b  

^a THE WALTON CENTRE NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT;

ADOLESCENT; ARTICLE; CHILD; CLINICAL PROTOCOL; DISEASE MANAGEMENT; DRUG RESISTANCE; HUMAN; MYOCLONUS EPILEPSY; PHYSIOLOGY; TREATMENT FAILURE;

ADOLESCENT; ANTICONVULSANTS; CHILD; CLINICAL PROTOCOLS; DISEASE MANAGEMENT; DRUG RESISTANCE; HUMANS; MYOCLONIC EPILEPSY, JUVENILE; TREATMENT FAILURE;

EID: 77955762953     PISSN: 14747758     EISSN: 14747766     Source Type: Journal    
DOI: 10.1136/jnnp.2010.217976     Document Type: Article

References (67)

1. Duncan JS. Idiopathic generalized epilepsies with typical absences. J Neurol 1997;244:403-11.
2. Panayiotopoulos CP, Obeid T, Waheed G. Absences in juvenile myoclonic epilepsy: a clinical and video-electroencephalographic study. Ann Neurol 1989;25:391-7.
3. Panayiotopoulos C.P, Obeid T, Waheed G. Differentiation of typical absence seizures in epileptic syndromes. A video EEG study of 224 seizures in 20 patients. Brain 1989;112 (Pt 4):1039-56.
4. Appleton R, Beirne M, Acomb B. Photosensitivity in juvenile myoclonic epilepsy. Seizure 2000;9:108-11.
5. Lancman ME, Asconapé JJ, Penry JK. Clinical and EEG asymmetries in juvenile myoclonic epilepsy. Epilepsia 1994;35:302-6.
6. Panayiotopoulos CP, Chroni E, Daskalopoulos C, et al. Typical absence seizures in adults: clinical, EEG, video-EEG f ndings and diagnostic/syndromic considerations. J Neurol Neurosurg Psychiatry 1992;55:1002-8.
7. Aliberti V, Grünewald RA, Panayiotopoulos CP,et al. Focal electroencephalographic abnormalities in juvenile myoclonic epilepsy. Epilepsia 1994;35:297-301.
8. Christe W, Janz D. Sodium valproate in idiopathic generalized epilepsies. Boll Lega Ital Epil 1988;61:11-15.
9. Janz D, Christe W. Generalized epilepsies. In: Resor SR, Kutt H, eds. The medical treatment of epilepsy. New York, USA: Marcel Dekker, 1992:145-62.
10. Sato S, White BG, Penry JK, et al. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology 1982;32:157-63.
11. Callaghan N, O'Hare J, O'Driscoll D, et al. Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Dev Med Child Neurol 1982;24:830-6.
12. Wilder BJ, Ramsay RE, Murphy JV, et al. Comparison of valproic acid and phenytoin in newly diagnosed tonic-clonic seizures. Neurology 1983;33:1474-6.
13. Simon D, Penry JK. Sodium di-N-propylacetate (DPA) in the treatment of epilepsy. A review. Epilepsia 1975;16:549-73.
14. Feuerstein J. A long term study of monotherapy with sodium valproate in primary generalized epilepsy. Br J Clin Pract 1983;27:17-23.
15. Covanis A, Gupta AK, Jeavons PM. Sodium valproate: monotherapy and polytherapy. Epilepsia 1982;23:693-720.
16. Dulac O, Steru D, Rey E, et al. Monotherapie par le valproate de sodium dans les epilepsies de l'enfant. Arch Fr Pediatr 1982;39:135-40.
17. Villarreal HJ, Wilder BJ, Willmore LJ, et al. Effect of valproic acid on spike and wave discharges in patients with absence seizures. Neurology 1978;28 (Pt 1):886-91.
18. Erenberg G, Rothner AD, Henry CE, et al. Valproic acid in the treatment of intractable absence seizures in children: a single-blind clinical and quantitative EEG study. Am J Dis Child 1982;136:526-9.
19. Marson AG, Williamson PR, Clough H, et al. Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. Epilepsia 2002;43:505-13.
20. Heller AJ, Chesterman P, Elwes RD, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry 1995;58:44-50.
21. de Silva M, MacArdle B, McGowan M, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996;347:709-13.
22. Thilothammal N, Banu K, Ratnam RS. Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double-blind study. Indian Pediatr 1996;33:549-55.
23. Christe W, Krämer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997;26:451-60.
24. Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003;107:165-75.
25. Genton P, Gelisse P, Thomas P, et al. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 2000;55:1106-9.
26. Marson AG, Al-Kharusi AM, Alwaidh M, et al.; SANAD Study group. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassif able epilepsy: an unblinded randomised controlled trial. Lancet 2007;369:1016-26.
27. Smith D, Defalla BA, Chadwick DW. The misdiagnosis of epilepsy and the management of refractory epilepsy in a specialist clinic. QJM 1999;92:15-23.
28. Berkovic SF, Andermann F, Andermann E,et al. Concepts of absence epilepsies: discrete syndromes or biological continuum? Neurology 1987;37:993-1000.
29. Panayiotopoulos CP, Tahan R, Obeid T. Juvenile myoclonic epilepsy: factors of error involved in the diagnosis and treatment. Epilepsia 1991;32:672-6.
30. Bancaud J, Talairach J. Clinical semiology of frontal lobe seizures. Adv Neurol 1992;57:3-58.
31. Williamson PD. Frontal lobe seizures. Problems of diagnosis and classif cation. Adv Neurol 1992;57:289-309.
32. Schmidt D. Single drug therapy for intractable epilepsy. J Neurol 1983;229:221-6.
33. National Institute for Clinical Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. London: Clinical Guideline 20, 2004.
34. Kwan P, Brodie MJ. Early identif cation of refractory epilepsy. N Engl J Med 2000;342:314-19.
35. Nicolson A, Appleton RE, Chadwick DW, et al. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry 2004;75:75-9.
36. Schlumberger E, Chavez F, Palacios L, et al. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994;35:359-67.
37. Timmings PL, Richens A. Lamotrigine in primary generalised epilepsy. Lancet 1992;339:1300-1.
38. Buchanan N. The use of lamotrigine in juvenile myoclonic epilepsy. Seizure 1996;5:149-51.
39. Frank LM, Enlow T, Holmes GL, et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 1999;40:973-9.
40. Beran RG, Berkovic SF, Dunagan FM, et al. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy. Epilepsia 1998;39:1329-33.
41. Guerrini R, Dravet C, Genton P, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998;39:508-12.
42. Biraben A, Allain H, Scarabin JM, et al. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2000;55:1758.
43. Nakamura J, Tamura S, Kanda T, et al. Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice. Eur J Pharmacol 1994;254:83-9.
44. Kellett MW, Smith DF, Stockton PA, et al. Topiramate in clinical practice: f rst year's postlicensing experience in a specialist epilepsy clinic. J Neurol Neurosurg Psychiatry 1999;66:759-63.
45. Stephen LJ, Sills GJ, Brodie MJ. Topiramate in refractory epilepsy: a prospective observational study. Epilepsia 2000;41:977-80.
46. Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999;52:1330-7.
47. Biton V, Bourgeois BF; YTC/YTCE Study Investigators. Topiramate in patients with juvenile myoclonic epilepsy. Arch Neurol 2005;62:1705-8.
48. Kaminski RM, Matagne A, Leclercq K, et al. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 2008;54:715-20.
49. Berkovic SF, Knowlton RC, Leroy RF, et al. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 2007;69:1751-60.
50. Noachtar S, Andermann E, Meyvisch P, et al.; N166 Levetiracetam Study Group. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008;70:607-16.
51. Rosenfeld WE, Benbadis S, Edrich P, et al. Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies. Epilepsy Res 2009;85:72-80.
52. Naito H, Wachi M, Nishida M. Clinical effects and plasma concentrations of long-term clonazepam monotherapy in previously untreated epileptics. Acta Neurol Scand 1987;76:58-63.
53. Mikkelsen B, Birket-Smith E, Bradt S, et al. Clonazepam in the treatment of epilepsy. A controlled clinical trial in simple absences, bilateral massive epileptic myoclonus, and atonic seizures. Arch Neurol 1976;33:322-5.
54. Obeid T, Panayiotopoulos C P. Clonazepam in juvenile myoclonic epilepsy. Epilepsia 1989;30:603-6.
55. Shorvon SD. Clobazam. In: Shorvon SD, ed. Handbook of epilepsy treatment. Oxford: Blackwell Science, 2000:93-6.
56. Feely M, Calvert R, Gibson J. Clobazam in catamenial epilepsy. A model for evaluating anticonvulsants. Lancet 1982;2:71-3.
57. Schmidt D. Clobazam for treatment of intractable epilepsy: a critical assessment. Epilepsia 1994;35(Suppl 5):S92-5.
58. Clobazam has equivalent eff cacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Canadian Study Group for childhood epilepsy. Epilepsia 1998;39:952-9.
59. Marinas A, Villanueva V, Giráldez BG, et al. Eff cacy and tolerability of zonisamide in idiopathic generalized epilepsy. Epileptic Disord 2009;11:61-6.
60. Pisani F, Di Perri R, Perucca E, et al. Interaction of lamotrigine with sodium valproate. Lancet 1993;341:1224.
61. Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res 1997;26:423-32.
62. Craig JJ, Hunt SJ. Treating women with juvenile myoclonic epilepsy. Pract Neurol 2009;9:268-77.
63. Ng M, Devinsky O. Vagus nerve stimulation for refractory idiopathic generalised epilepsy. Seizure 2004;13:176-8.
64. Holmes MD, Silbergeld DL, Drouhard D, et al. Effect of vagus nerve stimulation on adults with pharmacoresistant generalized epilepsy syndromes. Seizure 2004;13:340-5.
65. Fisher R, Salanova V, Witt T, et al. The SANTE study group. Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. Epilepsia 2010 Mar 17. [Epub ahead of print].
66. Ochs R, Gloor P, Quesney F, et al. Does head-turning during a seizure have lateralizing or localizing signif cance? Neurology 1984;34:884-90.
67. Montalenti E, Imperiale D, Rovera A, et al. Clinical features, EEG f ndings and diagnostic pitfalls in juvenile myoclonic epilepsy: a series of 63 patients. J Neurol Sci 2001;184:65-70.